Intensity of Myoclonus movements. -
Conditions
Interventions
Intervention 1: Intervention group 1: Granistron group: Patients in this group receive 40 µ g / kg as a pro drug 120 seconds before induction with etomidate. The volume of the above drug is 5 cc and i
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Elective surgery ASA I,II . Age between 15-60 years Having anesthesia condition
Exclusion criteria
Exclusion criteria: 1- Adrenal dysfunction- Sensitivity to drugs Mental disorders Neuromuscular disease Convulsions Electrolyte disorders History of addiction Prolonged QT and cardiovascular disease High ICP and IOP Increased intra-abdominal pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intensity of myoclonus movements after intravenous injection of etomidate. Timepoint: Once immediately after intravenous etomidate. Method of measurement: Myoclonus intensity with a score between 0 and 3 including 0 (without myoclonus), 1 or mild (gentle movements of a part of the body such as finger or wrist), 2 or moderate (gentle movements of 2 different muscle groups such as face and legs), 3 or severe (movements Severe clonic is measured in 2 or more muscle groups or rapid limb adduction). | — |
Secondary
| Measure | Time frame |
|---|---|
| Vital Sign Measurement (MAP). Timepoint: MAP is measured and recorded 60 seconds before and after injection of each drug under study (sufentanil and granisterone). Method of measurement: Through monitoring connected to the patient.;Vital Sign Measurement (HR). Timepoint: HR is measured and recorded 60 seconds before and after injection of each drug under study (sufentanil and granisterone). Method of measurement: Through monitoring connected to the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Alipour
Mashhad University of Medical Sciences
Outcome results
None listed